|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
REVIEW ARTICLE
From the Academic Unit of Child Health, University of
Manchester, St Mary's Hospital, Manchester, and the Paediatric
Immunology and Infectious Diseases Unit, Newcastle General Hospital,
Newcastle upon Tyne, United Kingdom.
Human primary immunodeficiency diseases are experiments of nature
characterized by an increased susceptibility to infection. In many
cases, they are also associated with troublesome and sometimes life-threatening autoimmune complications. In the past few years, great
strides have been made in understanding the molecular basis of primary
immunodeficiencies, and this had led to more focused and successful
treatment. This review has 3 aims: (1) to highlight the variety of
autoimmune phenomena associated with human primary immunodeficiency
diseases; (2) to explore how primary immunodeficiencies predispose
patients to autoimmune phenomena triggered by opportunistic infections;
and (3) to consider the rationale for the current treatment strategies
for autoimmune phenomena, specifically in relation to primary
immunodeficiency diseases. Reviewing recent advances in our
understanding of the small subgroup of patients with defined causes for
their autoimmunity may lead to the development of more effective
treatment strategies for idiopathic human autoimmune diseases.
(Blood. 2002;99:2694-2702) This review is limited largely to
immunodeficiency diseases in which the molecular basis of the condition
is understood, except in the case of common variable immunodeficiency
(CVID) and selective IgA deficiency (SIgAD), which are the most common
primary immunodeficiency diseases and which are often associated with
autoimmune phenomena. Most primary immunodeficiency diseases have been
reviewed recently, and we therefore will not here provide a
comprehensive account of all the features of each condition; rather, we
will focus on the interrelation among human primary immunodeficiency
and autoimmunity. Recent developments in our understanding of the
pathogenesis of multigenic autoimmune diseases, including the role of
HLA genes and the thymus, were reviewed elsewhere and are not discussed here.1-4 The use of bone marrow transplantation (BMT) in
the treatment of severe primary immunodeficiencies, a procedure that may either precipitate or ameliorate autoimmunity, was recently extensively reviewed.5
For many primary immunodeficiency diseases, the basis of the
autoimmunity is the inability of the host to eradicate microbial pathogens and their antigens completely through the usual immune pathways. The result is a compensatory, often exaggerated and chronic
inflammatory response by less effective alternative immune pathways,
which damage not only infected cells but also surrounding tissue
(Figure 1). Thus, in many affected
patients, autoimmunity is not a breakdown of tolerance to
self-antigens; rather, it is tissue damage incurred as the host
attempts to rid itself of foreign immunogens.6,7
Classification of autoimmune phenomena in primary
immunodeficiency diseases is problematic. One method of classification
is based on the underlying genetic defect. This results in a
long list that does little to help clinicians plan treatment strategy (Table 1). An alternative classification
system is based on the proposed immune pathway causing the autoimmunity
(Table 2). This may seem more logical
because it indicates the part of the immune system that must be
suppressed to control the problem. However, suppression of compensatory
immune pathways may not only decrease the inflammation causing the
autoimmunity but may also leave the patient open to overwhelming sepsis
and death. Furthermore, the problem is likely to recur after the
immunosuppression has been reduced because the underlying primary
immunodeficiency has not been corrected. A third method of
classification Phagocyte disorders
Chronic granulomatous disease.
Chronic granulomatous disease (CGD) consists of a group of X-linked and
autosomal recessive disorders of neutrophil production of nicotinamide
adenine dinucleotide phosphate oxidase that affect 1 in 200 000
children. In these disorders, neutrophils are incapable of completely
eradicating phagocytosed catalase-positive bacteria and fungi. Patients
have recurrent bacterial and fungal (especially Aspergillus)
infections that may affect any part of the body, including the skin,
lungs, liver, and bone. Death is usually caused by respiratory failure.
The average patient survives to the age of 20 years.8,9
Leukocyte adhesion molecule deficiency. Leukocyte adhesion molecule deficiency (LAD) is due to defects in integrin family adhesion molecules (CD18) that are essential for binding of neutrophils to the endothelial surface as a prerequisite to infiltration into inflamed tissues. Consequently, patients with LAD have high circulating neutrophil counts, resulting in severe, recurrent life-threatening infections associated with a lack of pus formation.15 Persistence of bacterial antigens and the inability of neutrophils to escape from the circulation may produce a persistent leukocytoclastic vasculitis. Early death can be averted only by BMT. Major histocompatibility complex class I deficiency (bare lymphocyte syndrome type I) Major histocompatibility complex class I (MHC I) deficiency is rare and has a variable clinical phenotype that ranges from totally asymptomatic to a condition similar to that resulting from severe combined immunodeficiency (SCID).16 Mutations in the genes coding for the transporter associated with antigen presentation (TAP) have been found in patients with this disorder. TAP mediates the translocation of foreign peptide from the proteasome into the endoplasmic reticulum so that it can combine with HLA-I molecules, an essential step in the presentation of MHC I-peptide complexes on the cell surface. Patients deficient in TAP have reduced cell-surface expression of MHC I. Immunity to viruses appears intact, with normal antibody titers, but chronic recurrent bacterial sinopulmonary infections are a major problem and patients have a course similar to those of patients with cystic fibrosis and ciliary dyskinesia. Chronic pulmonary infection may cause a reactive cutaneous leukocytoclastic vasculitis and a polyarthritis.16 Necrotizing granulomatous inflammation of the nose and skin may resemble manifestations of Wegener granulomatosis or lethal midline granuloma.17 Histologic assessment of the granuloma shows large numbers of activated natural killer (NK) cells. Unlike patients with Wegener granulomatosis, patients with MHC I deficiency do not have glomerulonephritis or proteinase 3-antineutrophil cytoplasmic antibodies. Immunosuppressive therapy using steroids and cyclophosphamide worsens the clinical condition because it dampens the host immune response to the chronic infection. Care of these patients should include regular chest physiotherapy and antibiotic therapy.Antibody production appears to be intact in MHC I deficiency, since patients have normal viral titers and a polyclonal hypergammaglobulinemia. Cellular immunity also appears to be unaffected: NK-cell-mediated and T-cell-mediated immunity to viruses is normal and skin testing using purified tuberculin may yield positive results. Thus, it is not known why patients with this disorder are susceptible to pyogenic bacterial infections. NK-cell disorders Chediak-Higashi syndrome and Griscelli syndrome. These syndromes are autosomal recessive diseases characterized by partial oculocutaneous albinism, a mild predisposition to pyogenic infections, and in Chediak-Higashi syndrome (CHS), abnormally large granules in many different cell types.18 Griscelli syndrome is differentiated from CHS by the presence of pathognomonic light and electron microscopical features in skin and hair and the absence of consistent granulocyte abnormalities. Mutations in the large lysosomal trafficking regulator gene that lead to truncation of the protein cause CHS.19,20 Mutations in the guanosine triphosphate (GTP)-binding protein RAB27A, which is involved in cytotoxicity and cytolytic granule exocytosis pathways, occur in Griscelli syndrome.21 Susceptibility to infection in patients with these syndromes may be due to defects in NK- and T-cell-mediated cytotoxicity, especially to herpes viruses, as well as defects in chemotaxis and the bactericidal capacity of granulocytes and monocytes. The accelerated phase of the disease, which is characterized by virus-induced hemophagocytic lymphohistiocytosis (HLH), has never been observed in animal models, possibly because the Epstein-Barr virus (EBV) is specific to humans.22 Many children with CHS or Griscelli syndrome will die young, largely as a result of EBV-triggered HLH, unless treated with BMT.Familial hemophagocytic lymphohistiocytosis. Familial hemophagocytic lymphohistiocytosis (FHL) is a rare, rapidly fatal autosomal recessive immune disorder characterized by uncontrolled activation of T cells and macrophages and overproduction of inflammatory cytokines. The disease is due to a defect in the perforin gene.23 Perforins are a class of proteins present in the secretory granules of NK and T lymphocytes that mediate cytotoxicity by polymerizing to form pores in target-cell membranes in a way similar to that of a structurally related protein, complement factor C9. Although FHL is considered a NK-cell disorder, its pathogenesis involves dysfunction of T cells. Incomplete clearance of triggering viruses results in a persistent, exaggerated inflammatory response with tissue destruction. After control of the HLH with immunosuppressive drugs, the treatment of choice is BMT.24,25 X-linked lymphoproliferative disease. X-linked lymphoproliferative disease (XLP), previously called Duncan disease,26 is due to a defect in SLAM-associated protein.27,28 The disease is characterized by an inability to mount an effective immune response to EBV. EBV-driven B-cell lymphoproliferative disease develops in 30% of patients and is usually fatal. Alternatively, persistent infection may be associated with an ineffectual but damaging T-cell-mediated inflammatory response. If generalized, the result is virus-associated HLH (58%); if more localized to the infected lymphocytes, aplastic anemia (3% of patients) or isolated hypogammaglobulinemia (31%) may develop.29 Three percent of boys have an exaggerated T-lymphocyte response to EBV-infected B cells lodging in lung tissue and vessel walls, resulting in pulmonary lymphomatoid granulomatosis associated with a lymphoid vasculitis.30,31 A similar T-cell reaction has been observed in boys with Wiskott-Aldrich syndrome (WAS).32 Aggressive combination chemotherapy with or without radiotherapy33 and interferon- 2b therapy34 have produced encouraging
improvements in survival of patients with lymphomatoid granulomatosis.
Anti-B-cell monoclonal antibodies that destroy B cells some of which
are infected with EBVhave also been used with some success to treat
this condition.35
The immune mechanisms underlying the clinical features of XLP are
becoming clearer. Defective NK-cell and cytotoxic T-lymphocyte activity
due to aberrant activity of the cytoplasmic lymphocyte activation
proteins 2B4 and SLAM result in persistence of the EBV virus that leads
to serious clinical disease.36-38 Reduced NK-cell activity
has been found in other patients with unusually severe or prolonged EBV
infections.39-42 Augmented activation of NK cells by
recombinant interleukin 2 has been used successfully to treat patients
with chronic EBV infection,43 although it has not so far
been used in XLP.
The prognosis for XLP is extremely poor, with 70% of boys dying before
the age of 10 years.29 As with many other rare
immunodeficiencies, BMT before tissue damage occurs is recommended.
Children who present with virus-associated HLH have been treated
successfully with HLH chemotherapy protocols.44
Complement deficiencies Deficiencies in components of complement are rare, with the most common being a deficiency in C2 that occurs in 1 in 20 000 people. Only deficiencies in the earlier components of the classical pathway (C1q, C1r, C1s, C2, and C4) have been linked to autoimmune diseases.45,46 One percent of patients with systemic lupus erythematous (SLE) have defects in their complement pathway. C1q deficiency occurred with SLE in 38 of 41 cases (92%) reported. Among such patients, SLE tends to be more severe, the age of onset is earlier (median age, 7 years), and a preponderance of male patients is observed. Patients with deficiencies in C1r and C1s that often occur together and C4 deficiencies have a similar propensity to SLE (60%-75%). Homozygous C2 deficiency is associated with SLE, SLE-like disease, or immune complex disease in 50% of cases. Heterozygous complement deficiencies do not produce an increased prevalence of autoimmunity. A deficiency of mannose-binding protein, which cleaves C4 and C2 when bound to antibody in the same way as activated C1s, has been linked to an increase in autoimmune disorders (arthritis, idiopathic thrombocytopenic purpura [ITP], enteropathy, pernicious anemia, and vitiligo) when associated with CVID.47 The exact mechanism by which complement deficiencies cause autoimmunity is unknown. The fact that it is C1q that binds to the Fc component of IgG or IgM and apoptotic cells suggests that the lack of interaction of complement with immunoglobulin and these cells may prevent the cells' clearance, thereby leading to production and buildup of circulating autoantibodies.48,49T-cell disorders Omenn syndrome. Omenn syndrome is a form of SCID associated with ineffectual T-lymphocyte responses to all infections. Patients have overwhelming viral, bacterial, fungal, or parasitic infections leading to death in infancy. The disorder is caused by mutations in recombination-activating genes (RAG) 1 and 2 that result in a partial absence of the protein product.50,51 RAG is involved in immunoglobulin and T-cell-receptor gene recombination and thus the generation of immune diversity. Defective development of lymphocytes causes a systemic autoimmune reaction (with lymphadenopathy, splenomegaly, erythroderma, autoimmune hepatic dysfunction and failure, and encephalopathy) that is similar to HLH and that characterizes Omenn syndrome.52,53 Children with Omenn syndrome will die unless treated with BMT. Dysfunctional T-lymphocyte activity is controlled by administering a combination of high-dose steroids, antithymocyte globulin, and cyclosporin A (HLH protocol) before transplantation. Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (autoimmune polyglandular syndrome type 1). Autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) is a rare autoimmune disease that primarily affects the endocrine glands.54 The typical triad for APECED is hypoparathyroidism (85% of patients), primary adrenocortical failure (72%), and chronic mucocutaneous candidiasis (100%). Gonadal failure (60%), diabetes mellitus (18%), and pernicious anemia (13%) may also occur. Ectodermal manifestations include dystrophy of the dental enamel (77%) and nails (52%). The most life-threatening complications are oral squamous cell carcinoma and fulminant autoimmune hepatitis. The disease prevalence is especially high in Finland, among Iranian Jews, and in the Sardinian population. Mutations in the autoimmune regulator (AIRE) gene cause this organ-specific human autoimmune disease.55 It was suggested that through transcriptional regulation, AIRE is involved in the negative selection or anergy induction of self-reactive lymphocytes in the thymus.56-59 Patients with chronic mucocutaneous candidiasis (CMC) have similar problems with Candida infections and autoimmune polyendocrinopathies but no ectodermal dysplasia. The underlying gene defect in CMC is unknown.60Autoimmune lymphoproliferative syndrome. Patients with type I Autoimmune lymphoproliferative syndrome (ALPS; Canale-Smith syndrome) have a defect in Fas, a member of the tumor necrosis factor (TNF) superfamily.61,62 A mutation in caspase 10, another cellular component of the same apoptotic pathway, has been found in patients with type II ALPS.63 ALPS does not produce an overt increase in propensity to infections. The principal clinical features are chronic benign lymphoproliferation (lymphadenopathy and splenomegaly) and autoimmune disease (especially autoimmune cytopenias, although other organ-specific autoimmune phenomena also occur).62,64 The precise trigger for the clinical features of the disease is still unknown, but common childhood herpes virus infections (human herpesvirus 6, cytomegalovirus, and EBV infections) that induce a lymphoproliferative response though cleared normally may be involved.65 The prognosis for children with Fas deficiency is generally good unless they have the very rare homozygous form of the disease, for which early BMT is recommended. The heterozygous form tends to improve spontaneously with age and without treatment. Patients and their families appear to have an increased risk of both Hodgkin (51-fold increase) and non-Hodgkin (14-fold increase) lymphomas.66CD40 ligand deficiency (hyper-IgM syndrome). CD40 ligand (CD40L), like Fas, is a member of the TNF superfamily, involved in T-cell-mediated cytolysis and T-cell-dependent, B-cell antibody responses. It is the gene underlying the X-linked form of hyper-IgM syndrome.67 Defects in the activation-inducing cytidine deaminase gene cause an autosomal recessive form of the disorder.68 Hyper-IgM syndrome was initially characterized as a humoral immunodeficiency with a delay in the class switching from IgM production (normal or high levels of serum IgM) to immunoglobulin molecules of other classes (low IgG, IgA, and IgE levels) associated with sinopulmonary infections.69 Pneumocystis carinii pneumonia (PCP) is common in patients with hyper-IgM syndrome but is not characteristic of humoral immunodeficiencies. The increased prevalence of PCP is not related to the humoral immune abnormalities but is due to the inability of T lymphocytes to induce apoptosis of pulmonary epithelium infected with Pneumocystis organisms.70 A principal cause of death in patients with hyper-IgM syndrome who reach adolescence or young adulthood is liver failure due to sclerosing cholangitis.71,72 The mechanism for this organ-specific autoimmune phenomenon has been described. Cryptosporidium gastroenteritis is common in these patients, and Cryptosporidium parasites may also ascend the biliary tree and infect bile duct epithelium. The inability of T lymphocytes to induce destruction of infected cells results in persistence of the pathogen, chronic inflammation, and subsequently, sclerosing cholangitis.73 In contrast to the increase in destructive cellular immune responses, patients with CD40L deficiency have a reduction in self-reactive antibodies, a finding that illustrates the essential role of functional interactions between CD40 and CD40L in the selection of natural self-reactive B-cell repertoires.74 The long-term prognosis for patients with hyper-IgM syndrome is poor; 50% of boys with the disorder are dead by the age of 20 years. Definitive treatment with BMT in early childhood is recommended.75 Children who undergo BMT after liver damage occurs have a significantly poorer outcome post-BMT, largely because of graft-versus-host disease in the diseased liver that results in liver failure and often death if liver transplantation is not done.76,77MHC class II deficiency. MHC II deficiency consists of a group of rare autosomal recessive conditions caused by mutations in 4 genetic complementation groups or regulatory proteins involved in MHC II gene expression.78 All cells derived from bone marrow, as well as thymic epithelium critical for the maturation of CD4+ T cells, have no MHC class II expression and a resultant CD4+ T lymphopenia. Patients with MHC class II deficiency usually die in infancy of overwhelming infections, especially disseminated viral infections.79-81 BMT is the only curative therapy, although success rates are lower than for SCID and the CD4+ T lymphopenia persists.82 As with CD40L deficiency, incomplete clearance of parasites can lead to Cryptosporidium-associated sclerosing cholangitis (up to 16% of cases). Autoimmune cytopenias also occur in up to 19% of patients.83 Wiskott-Aldrich syndrome. WAS is a rare X-linked immunodeficiency disorder caused by a maturational defect affecting both lymphocytes and platelets. Death in childhood (mean age, 11 years) is due to hemorrhage (23% of patients), infection (44%), or EBV-driven lymphomas (26%).84 Eczema is common (81%); autoimmune problems occur in children with the more severe phenotype (40%) and are associated with an increased risk of EBV-related lymphoid cancer (P < .001). In a review, Sullivan et al85 observed that 15 of 20 nonperitransplantation cases of malignant disease (75%) occurred in patients with a history of autoimmune disease. Conversely, malignant disease ultimately developed in 25% of patients with a history of autoimmune disease but in just 5% of patients without such a history. These data suggest that EBV, which underlies malignant disease in patients with WAS, may also trigger the autoimmunity. The most common autoimmune problems are hemolytic anemia and vasculitis, followed by renal disease and arthritis. In some boys, clinical features similar to those in Kawasaki disease are observed.86 SLE, Sjögren syndrome, autoimmune endocrinopathies, and sarcoidosis do not occur.85 The gene responsible for WAS (WAS protein) is expressed in all hematopoietic stem cell-derived lineages and may play a role in the regulation of the actin-cytoskeleton system by interacting directly with the P-like GTPase cdc42.87,88 The immune problems in WAS are not static, and there is a continual deterioration in immune function. Symptomatic treatment with intravenous immunoglobulin, splenectomy, steroids, and antibiotic prophylaxis should be used only as a holding measure.85,89 It is clear that BMT is the treatment of choice and should be done before patients reach school age and have cumulative tissue damage due to infection and autoimmune disease.86Common variable immunodeficiency. CVID is the most common symptomatic primary antibody deficiency syndrome. It is characterized clinically by recurrent sinopulmonary and gastrointestinal infections. Chronic bronchiectasis leading to respiratory failure is a common cause of premature death. Many patients require immunoglobulin-replacement therapy, prophylactic antibiotic treatment, or both. CVID is not a single disease but an idiopathic group of diseases characterized by various degrees of defective antibody production, ranging from isolated defects in the production of antibody to carbohydrate antigens to almost complete absence of all immunoglobulin subclasses.90 Leaky phenotypes of SCIDs and the molecular defects listed in Table 4 are sometimes found in patients presenting with clinical features suggestive of CVID. A greater understanding of the molecular genetic background of primary immunodeficiency disorders will lead to a smaller proportion of patients being considered to have CVID and a larger proportion given a diagnosis of a defined primary immunodeficiency disease. This will allow more accurate advice to be given on the possible complications and likely natural history of a patient's condition.
Isolated IgA deficiency or SIgAD. SIgAD is the most common form of primary immunodeficiency disease in the Western world (1 in 600), although it is less common in the Japanese (1 in 18 000) and Chinese (1 in 4000) populations.103 Familial inheritance of either SIgAD or CVID occurs in about 20% of cases, and CVID may develop from SIgAD, suggesting that at least in some cases, SIgAD and CVID may be part of a spectrum of diseases caused by common, not-yet-identified genetic factors.94 Most people with SIgAD are asymptomatic and do not have an increased risk of infection. Patients with recurrent infections, particularly respiratory and gastrointestinal infections, often have other antibody defects and are therefore more appropriately classified as having CVID. Patients with SIgAD have an increased risk of autoimmune phenomena, especially systemic autoimmune diseases such as SLE (1%-5% of patients) and rheumatoid arthritis (2%-4% of patients).104 There is also a clear link between SIgAD and celiac disease. The prevalence of SIgAD in patients with celiac disease is 2.6%, which represents a 10- to 16-fold increase over that in the general population.105 An increased risk of other organ-specific autoimmune diseases, such as insulin-dependent diabetes mellitus, myasthenia gravis, and autoimmune thyroiditis, has been reported, but the evidence for such associations is insufficient, and larger studies are required before definite conclusions can be drawn. A high prevalence of autoantibodies (especially rheumatoid factor, anticardiolipin, and antinuclear antibodies) not associated with any clinical disease occurs in patients with SIgAD.104 Antibodies against ingested food antigens are also common. Anti-IgA antibodies, especially those of the IgG subclass, are found in 9% to 44% of patients with complete, but not partial, SIgAD. Although reactions to blood products in patients with SIgAD are uncommon (1 in 30),106 anti-IgA antibodies increase the risk of severe or even fatal reactions to blood, plasma, and agents used in immunoglobulin-replacement therapy.107 There is no correlation between the titer of anti-IgA antibodies of the IgG and IgM class and the severity of transfusion reactions. The risk of anaphylaxis may be related to the production of antibodies of the IgE isotype.108 Blood products should be administered with caution to patients with SIgAD, and intravenous immunoglobulin products with low levels of IgA (< 1 mg/L) are often recommended.109 There are several theories for why patients with SIgAD have an increased risk of autoimmunity. IgA on mucosal surfaces may bind to environmental antigens, promoting their removal and preventing development of secondary T-cell-mediated inflammatory responses. Certain HLA alleles and haplotypes (eg, HLA-A1, HLA-B8, and HLA-DR3) associated with autoimmune diseases are also associated with SIgAD.110 Production of IgA is known to be strictly T-cell dependent, and some patients with SIgAD have CVID and overt abnormalities in T-cell regulation. T-cell dysfunction may be responsible for both SIgAD and the autoimmunity.104DiGeorge syndrome. A few anecdotal reports have described immune cytopenias and ITP in children with 22q11 deletions (DiGeorge syndrome).111,112 Additional studies are required to determine the extent to which autoimmune diseases occur in patients with this T-cell immunodeficiency. Cytokine storms Hereditary febrile disorders. Some rare disorders are characterized by recurrent episodes of fever and autoimmune phenomena. Familial Mediterranean fever (FMF) is an autosomal recessive disorder that chiefly affects people from the Mediterranean basin and is caused by mutations in the pyrin-marenostrin (MEFV) gene.113 MEFV, a member of a highly conserved group of nuclear transcription factor genes, is expressed in neutrophils, eosinophils, and monocytes114 and is thought to provide inhibitory signals that may decrease inflammatory responses by these cells.115 FMF is characterized clinically by recurrent episodes of fever, polyserositis, and arthritis, which occurs in almost half of the patients and is usually monoarticular. Up to 47% of patients have Henoch-Schönlein purpura with a leukocytoclastic vasculitis, and 9% have polyarteritis nodosa.116-118 In one series, 12 of 16 patients had high levels of antistreptolysin O titer, suggesting a possible role for streptococcal infections in triggering the vasculitis.117 Amyloidosis develops in 25% of patients. Colchicine is the treatment of choice for both prophylaxis and acute exacerbations of FMF. TNF-receptor (TNFR)-associated periodic syndrome (TRAPS) is an autosomal dominant condition caused by missense mutations in the gene encoding type I TNFR.119 The mutations may produce an inability to cleave the extracellular domain of the TNFR, thereby leading to a persistent, exaggerated response to TNF. Patients with TRAPS may have fever, polyserositis, arthritis, rash, and conjunctivitis; amyloidosis occurs in 25%. Clinical improvement in TRAPS has been observed after infusions of p75 TNFR-Fc fusion proteins.118 Hyperimmunoglobulinemia D and periodic fever syndrome, in which patients have fever, polyserositis, arthritis, lymphadenopathy, and cutaneous vasculitis, is due to mutations in the gene encoding mevalonate kinase.120 Mevalonic kinase catalyzes conversion of mevalonic acid to 5-phosphomevalonic acid during biosynthesis of cholesterol and nonsterol isoprene compounds, but the mechanism by which mutations in the gene cause inflammation is unknown. Nonsteroidal anti-inflammatory agents may partly control symptoms.
It is currently assumed that autoimmunity is a breakdown in self-tolerance. However, advances in our understanding suggest that autoimmunity associated with primary immunodeficiency diseases is not simply defective self-tolerance; rather, it is the inability of an inherently defective immune system to eradicate persisting microbial immunogens. Persistence of an antigen results in chronic, ineffective, damaging immune responses (Table 2). Herpes viruses are the archetypal persisting infectious agents that, even in individuals with essentially normal immunity, intermittently escape from normal immune control and produce symptomatic disease. It is therefore not surprising that incomplete eradication or relapse of EBV seems to trigger autoimmune phenomena. Examples include virus-associated HLH in CHS, Griscelli syndrome, FHL, and XLP; lymphomatoid vasculitis in XLP and lymphomatoid vasculitis; and possibly other vasculitides in WAS. Most animals are resistant to EBV, and the classic virus-associated HLH of the NK-cell disorders does not occur, limiting the usefulness of animals as models for these diseases. Boys with X-linked agammaglobulinemia have no B lymphocytes and therefore cannot be chronically infected with EBV. Autoimmunity is not a feature of this B-cell disorder. This review highlighted the great variety of genetic defects that may predispose an individual to autoimmunity (Table 1). Mutated genes are involved in a variety of cellular functions. In some cases, it is difficult to reconcile the underlying genetic defect (eg, MEFV and mevalonate kinase) with the clinical disease, and therefore candidate-gene screening approaches may not always be useful. The fact that mutations in a variety of genes may result in almost identical clinical phenotypes (eg, HLH in XLP and FHL and ALPS in Fas and caspase-10 deficiency) is likely to complicate population studies aimed at determining genetic predisposition for specific autoimmune syndromes. Studies in animals will help explain why a particular autoimmune disease develops in a particular inbred strain, but results should be applied cautiously to human disease. Despite these difficulties, studies of autoimmunity in primary immunodeficiency diseases and of their underlying molecular defects have allowed clinicians to predict the natural history of these conditions and to optimize clinical management. In our pediatric immunology practice, we have created strong collaborative links with clinical colleagues in other specialties, including rheumatology, gastroenterology, and particularly hematology, as well as with scientists in laboratories around the world. This has led to a diagnosis in several patients and their relatives, some of whom were thought to have had an "idiopathic" autoimmune disease for many years. Strengthening of links and communication among clinicians in a variety of specialties and development of collaborative research with basic scientists has and will continue to provide the best means for translating the advances in understanding autoimmunity in primary immunodeficiency diseases to idiopathic autoimmunity.
Submitted August 10, 2001; accepted December 4, 2001.
Reprints: P. D. Arkwright, Academic Unit of Child Health, First Floor, St Mary's Hospital, Hathersage Road, Manchester, M13 0JH, United Kingdom; e-mail: peter_arkwright{at}lineone.net.
1.
Davidson A, Diamond B.
Autoimmune diseases.
N Engl J Med.
2001;345:340-350 2. Marrack P, Kappler J, Kotzin BL. Autoimmune disease: why and where it occurs. Nat Med. 2001;7:899-905[CrossRef][Medline] [Order article via Infotrieve]. 3. Sonderstrup G, McDevitt HO. DR, DQ and you: MHC alleles and autoimmunity. J Clin Invest. 2001;107:795-796[Medline] [Order article via Infotrieve]. 4. Theofilopoulos AN, Dummer W, Kono DH. T cell homeostasis and systemic autoimmunity. J Clin Invest. 2001;108:335-340[CrossRef][Medline] [Order article via Infotrieve]. 5. Sherer Y, Shoenfeld Y. Autoimmune diseases and autoimmunity post-bone marrow transplantation. Bone Marrow Transplant. 1998;22:873-881[CrossRef][Medline] [Order article via Infotrieve]. 6. Fairweather D, Kaya Z, Shellam GR, Lawson CM, Rose NR. From infection to Autoimmunity. J Autoimmun. 2001;16:175-186[CrossRef][Medline] [Order article via Infotrieve]. 7. Panoutsakopoulou V, Cantor H. On the relationship between viral infection and autoimmunity. J Autoimmun. 2001;16:341-345[CrossRef][Medline] [Order article via Infotrieve].
8.
Finn A, Hadzic N, Morgan G, Strobel S, Levinsky RJ.
Prognosis of chronic granulomatous disease.
Arch Dis Child.
1990;65:942-945 9. Winkelstein JA, Marino MC, Johnston RB Jr, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore). 2000;79:155-169[CrossRef][Medline] [Order article via Infotrieve]. 10. Ament ME, Ochs HD. Gastrointestinal manifestations of chronic granulomatous disease. N Engl J Med. 1973;288:382-387.
11.
Barton LL, Moussa SL, Villar RG, Hulett RL.
Gastrointestinal complications of chronic granulomatous disease: case report and literature review.
Clin Pediatr.
1998;37:231-236 12. Rosh JR, Tang HB, Mayer L, Groisman G, Abraham SK, Prince A. Treatment of intractable gastrointestinal manifestations of chronic granulomatous disease with cyclosporine. J Pediatr. 1995;126:143-145[CrossRef][Medline] [Order article via Infotrieve]. 13. Bratt J, Palmblad J. Cytokine-induced neutrophil-mediated injury of human endothelial cells. J Immunol. 1997;159:912-918[Abstract].
14.
Ozsahin H, von Planta M, Mueller I, et al.
Successful treatment of invasive aspergillosis in chronic granulomatous disease by bone marrow transplantation, granulocyte colony-stimulating factor-mobilizing granulocytes, and liposomal amphotericin-B.
Blood.
1998;92:2719-2724
15.
Etzioni A.
Adhesion molecules 16. Gadola SD, Moins-Teisserenc HT, Trowsdale J, Gross WL, Cerundolo V. TAP deficiency syndrome. Clin Exp Immunol. 2000;121:173-178[CrossRef][Medline] [Order article via Infotrieve]. 17. Moins-Teisserenc HT, Gadola SD, Cella M, et al. Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules. Lancet. 1999;354:1598-1603[CrossRef][Medline] [Order article via Infotrieve]. 18. Sato A. Chediak-Higashi disease: probable identity of a "new leukocyte anomaly (Chediak)" and "congenital gigantism of peroxidase granules (Higashi)." Tohoya J Exp Med. 1955;61:201. 19. Barbosa MD, Nguyen QA, Tchernev VT, et al. Identification of the homologous beige and Chediak-Higashi syndrome genes. Nature. 1996;382:262-265[CrossRef][Medline] [Order article via Infotrieve]. 20. Nagle DL, Karim MA, Woolf EA, et al. Identification and mutation analysis of the complete gene for Chediak-Higashi syndrome. Nat Genet. 1996;14:307-311[CrossRef][Medline] [Order article via Infotrieve]. 21. Menasche G, Pastural E, Feldmann J, et al. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet. 2000;25:173-176[CrossRef][Medline] [Order article via Infotrieve]. 22. Windhorst DB, Padgett G. The Chediak-Higashi syndrome and the homologous trait in animals. J Invest Dermatol. 1973;60:529-537[CrossRef][Medline] [Order article via Infotrieve].
23.
Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al.
Perforin gene defects in familial hemophagocytic lymphohistiocytosis.
Science.
1999;286:1957-1959 24. Collins P, Watts M, Brocklesby M, Gerritsen B, Veys P. Successful engraftment of haploidentical stem cell transplant for familial haemophagocytic lymphohistiocytosis using both bone marrow and peripheral blood stem cells. Br J Haematol. 1997;96:644-646[CrossRef][Medline] [Order article via Infotrieve].
25.
Jabado N, de Graeff-Meeder ER, Cavazzana-Calvo M, et al.
Treatment of familial hemophagocytic lymphohistiocytosis with bone marrow transplantation from HLA genetically nonidentical donors.
Blood.
1997;90:4743-4748 26. Purtilo DT, Cassel CK, Yang JP, et al. X-linked recessive progressive combined variable immunodeficiency (Duncan's disease) Lancet. 1975;1:935-941[Medline] [Order article via Infotrieve]. 27. Coffey AJ, Brooksbank RA, Brandau O, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet. 1998;20:129-135[CrossRef][Medline] [Order article via Infotrieve]. 28. Sayos J, Wu C, Morra M, et al. The X-linked lymphoproliferative disease gene product SAP regulates signals induced through the co-receptor SLAM. Nature. 1998;395:462-469[CrossRef][Medline] [Order article via Infotrieve]. 29. Seemayer TA, Gross TG, Egeler RM, et al. X-linked lymphoproliferative disease: twenty-five years after the discovery. Pediatr Res. 1995;38:471-478[Medline] [Order article via Infotrieve]. 30. Ventri RW, Raich PC, McClung JE, Shah SH, Sprinkle PM. Lymphomatoid granulomatosis and Epstein-Barr virus. Cancer. 1982;50:1513-1517[CrossRef][Medline] [Order article via Infotrieve]. 31. Guinee D Jr, Jaffe E, Kingma D, et al. Pulmonary lymphomatoid granulomatosis. Evidence for a proliferation of Epstein-Barr virus infected B-lymphocytes with a prominent T-cell component and vasculitis. Am J Surg Pathol. 1994;18:753-764[Medline] [Order article via Infotrieve]. 32. Ilowite NT, Fligner CL, Ochs HD, et al. Pulmonary angiitis with atypical lymphoreticular infiltrates in Wiskott-Aldrich syndrome: possible relationship of lymphomatoid granulomatosis and EBV infection. Clin Immunol Immunopathol. 1986;41:479-484[CrossRef][Medline] [Order article via Infotrieve].
33.
Lipford EH, Margolick JB, Longo DL, Fauci AS, Jaffe ES.
Angiocentric immunoproliferative lesions: a clinicopathologic spectrum of post-thymic T-cell proliferations.
Blood.
1988;72:1674-1681
34.
Wilson WH, Kingma DW, Raffeld M, Wittes RE, Jaffe ES.
Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-
35.
Kuehnle I, Huls MH, Liu Z, et al.
CD20 monoclonal antibody (rituximab) for therapy of Epstein-Barr virus lymphoma after hemopoietic stem-cell transplantation.
Blood.
2000;95:1502-1505
36.
Welsh RM Jr, Zinkernagel RM, Hallenbeck LA.
Cytotoxic cells induced during lymphocytic choriomeningitis virus infection of mice, II: "specificities" of the natural killer cells.
J Immunol.
1979;122:475-481
37.
Benoit L, Wang X, Pabst HF, Dutz J, Tan R.
Cutting edge: defective NK cell activation in X-linked lymphoproliferative disease.
J Immunol.
2000;165:3549-3553
38.
Parolini S, Bottino C, Falco M, et al.
X-linked lymphoproliferative disease. 2B4 molecules displaying inhibitory rather than activating function are responsible for the inability of natural killer cells to kill Epstein-Barr virus-infected cells.
J Exp Med.
2000;192:337-346 39. Fleischer G, Starr S, Koven N, Kamiya H, Douglas SD, Henle W. A non-X-linked syndrome with susceptibility to severe Epstein-Barr virus infections. J Pediatr. 1982;100:727-730[CrossRef][Medline] [Order article via Infotrieve]. 40. Yanagisawa M, Kato M, Ikeno K, et al. Defective generation of killer cells against spontaneously Epstein-Barr virus (EBV)-transformed autologous B cells in a fatal EBV infection. Clin Exp Immunol. 1987;68:251-258[Medline] [Order article via Infotrieve]. 41. Joncas J, Monczak Y, Ghihu F, et al. Brief report: killer cell defect and persistent immunological abnormalities in two patients with chronic active Epstein-Barr virus infection. J Med Virol. 1989;28:110-117[Medline] [Order article via Infotrieve].
42.
Okano M, Matsumoto S, Osato T, Sakiyama Y, Thiele GM, Purtilo DT.
Severe chronic active Epstein-Barr virus infection syndrome.
Clin Microbiol Rev.
1991;4:129-135 43. Kawa-Ha K, Franco E, Doi S, et al. Successful treatment of chronic Epstein-Barr virus infection with recombinant interleukin-2. Lancet. 1987;1:154[CrossRef][Medline] [Order article via Infotrieve].
44.
Stephan J, Donadieu J, Le Deist F, Blauche S, Griscelli C, Fischer A.
Treatment of familial hemophagocytic lymphohistiocytosis with anti-thymocyte globulins, steroids and cyclosporin A.
Blood.
1993;82:2319-2323 45. Walport MJ, Davies KA, Morley BJ, Botto M. Complement deficiency and autoimmunity. Ann N Y Acad Sci. 1997;815:267-281[Medline] [Order article via Infotrieve].
46.
Truedsson L, Fredrikson GN, Sjoholm AG.
Complement deficiencies 47. Mullighan CG, Marshall SE, Welsh KI. Mannose binding lectin polymorphisms are associated with early age of disease onset and autoimmunity in common variable immunodeficiency. Scand J Immunol. 2000;51:111-122[CrossRef][Medline] [Order article via Infotrieve].
48.
Perniok A, Wedekind F, Herrmann M, Specker C, Schneider M.
High levels of circulating early apoptotic peripheral blood mononuclear cells in systemic lupus erythematosus.
Lupus.
1998;7:113-118
49.
Mevorach D, Zhou JL, Song X, Elkon KB.
Systemic exposure to irradiated apoptotic cells induce autoantibody production.
J Exp Med.
1998;188:387-392 50. Villa A, Santagata S, Bozzi F, et al. Partial V(D)J recombination activity leads to Omenn's syndrome. Cell. 1998;93:885-896[CrossRef][Medline] [Order article via Infotrieve]. 51. de Saint-Basile G, Le Deist F, de Villartay JP, et al. Restricted heterogeneity of T lymphocytes in combined immunodeficiency with hypereosinophilia (Omenn's syndrome). J Clin Invest. 1991;87:1352-1359. 52. Omenn GS. Familial reticuloendotheliosis with eosinophilia. N Engl J Med. 1965;273:427-432.
53.
Villa A, Sobacchi C, Notarangelo LD, et al.
V(D)J recombination defects in lymphocytes: a severe immunodeficiency with a spectrum of clinical presentations due to RAG mutations.
Blood.
2001;97:81-88 54. Ahonen P. Autoimmune polyendocrinopathy-candidosis-ectodermal dystrophy (APECED): autosomal recessive inheritance. Clin Genet. 1985;27:532-542. 55. Nagamine K, Peterson P, Hamish SS, et al. Positional cloning of the APECED gene. Nat Genet. 1997;17:393-398[CrossRef][Medline] [Order article via Infotrieve]. 56. Bjorses P, Halonen M, Palvimo JJ, et al. Mutations in the AIRE gene: effects on subcellular location and transactivation function of the autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy protein. Am J Hum Genet. 2000;66:378-392[CrossRef][Medline] [Order article via Infotrieve].
57.
Pitkanen J, Doucas V, Sternsdorf T, et al.
The autoimmune regulator protein has transcriptional transactivating properties and interacts with the common coactivator CREB-binding protein.
J Biol Chem.
2000;275:16802-16809
58.
Zuklys S, Bulciunaite G, Agarwal A, Fasler-Kan E, Palmer E, Hollander GA.
Normal thymic architecture and negative selection are associated with AIRE expression, the gene defective in the autoimmune-polyendocrinopathy-candidiasis-ectodermal dystrophy.
J Immunol.
2000;165:1976-1983
59.
Pitkanen J, Vahamurto P, Krohn K, Peterson P.
Subcellular localization of the autoimmune regulator protein. Characterization of nuclear targeting and transcriptional activation domain.
J Biol Chem.
2001;276:19597-19602
60.
Lilic D, Gravenor I.
Immunology of chronic mucocutaneous candidiasis.
J Clin Pathol.
2001;54:81-83 61. Canale VC, Smith CH. Chronic lymphadenopathy simulating malignant lymphoma. J Pediatr. 1967;70:891-899[CrossRef][Medline] [Order article via Infotrieve].
62.
Rieux-Laucat F, Blachere S, Danielan S, et al.
Lymphoproliferative syndrome with autoimmunity: a possible genetic basis for dominant expression of the clinical manifestations.
Blood.
1999;94:2575-2582 63. Wang J, Zheng L, Lobito A, et al. Inherited human caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. Cell. 1999;98:47-58[CrossRef][Medline] [Order article via Infotrieve].
64.
Sneller MC, Wang J, Dale JK, et al.
Clinical, immunologic and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.
Blood.
1997;89:1341-1348 65. Arkwright PD, Rieux-Laucat F, Le Deist F, Stevens RF, Angus B, Cant AJ. Cytomegalovirus infection in infants with autoimmune lymphoproliferative syndrome (ALPS). Clin Exp Immunol. 2000;121:353-357[CrossRef][Medline] [Order article via Infotrieve].
66.
Straus SE, Jaffe ES, Puck JM, et al.
The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis.
Blood.
2001;98:194-200 67. Banchereau J, Bazan F, Blanchard D, et al. The CD40 antigen and its ligand. Ann Rev Immunol. 1994;12:881-922[CrossRef][Medline] [Order article via Infotrieve]. 68. Revy P, Muto T, Levy Y, et al. Activation-induced cytidine deaminase (AID) deficiency causes the autosomal recessive form of the hyper-IgM syndrome (HIGM2). Cell. 2000;102:565-575[CrossRef][Medline] [Order article via Infotrieve]. 69. Allen RC, Armitage RJ, Conley ME, et al. CD40 ligand gene defects responsible for X-linked hyper-IgM syndrome. Science. 1993;259:990-993[Abstract]. 70. Wiley JA, Harmsen AG. CD40 ligand is required for resolution of Pneumocystis pneumonia in mice. J Immunol. 1995;155:3525-3529[Abstract]. 71. Levy J, Espanol-Boren T, Thomas C, et al. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr. 1997;131:47-54[CrossRef][Medline] [Order article via Infotrieve]. 72. Notarangelo LD, Hayward AR. X-linked immunodeficiency with hyper-IgM (XHIM). Clin Exp Immunol. 2000;120:399-405[CrossRef][Medline] [Order article via Infotrieve].
73.
Cosyns M, Tsirkin S, Jones M, Flavell R, Kikutani H, Hayward AR.
Requirement of CD40-CD40 ligand interaction for elimination of Cryptosporidium parvum from mice.
Infect Immun.
1998;66:603-607
74.
Lacroix-Desmazes S, Resnick I, Stahl D, et al.
Defective self-reactive antibody repertoire of serum IgM in patients with hyper-IgM syndrome.
J Immunol.
1999;162:5601-5608
75.
Thomas C, de Saint Basile G, Le Deist F, et al.
Brief report: correction of X-linked hyper-IgM syndrome by allogeneic bone marrow transplantation.
N Engl J Med.
1995;333:426-429
76.
Hadzic N, Pagliuca A, Rela M, et al.
Correction of the hyper-IgM syndrome after liver and bone marrow transplantation.
N Engl J Med.
2000;342:320-324
77.
Khawaja K, Gennery AR, Flood TJ, Abinun M, Cant AJ.
Bone marrow transplantation for CD40 ligand deficiency: a single centre experience.
Arch Dis Child.
2001;84:508-511 78. Masternak K, Barras E, Zufferey M, et al. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat Genet. 1998;20:273-277[CrossRef][Medline] [Order article via Infotrieve]. 79. Klein C, Lisowska-Grospierre B, LeDeist F, Fischer A, Griscelli C. Major histocompatibility complex class II deficiency: clinical manifestations, immunologic features and outcome. J Pediatr. 1993;123:921-928[CrossRef][Medline] [Order article via Infotrieve]. 80. Elhasid R, Etzioni A. Major histocompatibility complex class II deficiency: a clinical review. Blood Rev. 1996;10:242-248[CrossRef][Medline] [Order article via Infotrieve].
81.
Saleem MA, Arkwright PD, Davies EG, Cant AJ, Veys PA.
Clinical course of patients with major histocompatibility complex class II deficiency.
Arch Dis Child.
2000;83:356-359
82.
Klein C, Cavazzana-Calvo M, LeDeist F, et al.
Bone marrow transplantation in major histocompatibility complex class II deficiency: a single-center study of 19 patients.
Blood.
1995;85:580-587 83. Griscelli C, Lisowska-Grospierre B, Mach B. Combined immunodeficiency with defective expression in MHC class II genes. Immunodefic Rev. 1989;1:135-153[Medline] [Order article via Infotrieve]. 84. Cotelingham JD, Witebsky FG, Hsu SM, Blaese RM, Jaffe ES. Malignant lymphoma in patients with the Wiskott-Aldrich syndrome. Cancer Invest. 1985;3:515-522[Medline] [Order article via Infotrieve]. 85. Sullivan KE, Mullen CA, Blaese RM, Winkelstein JA. A multiinstitutional survey of the Wiskott-Aldrich syndrome. J Pediatr. 1994;125:876-885[CrossRef][Medline] [Order article via Infotrieve]. 86. Filipovich AH, Krivit W, Kersey JH, Burke BA. Fatal arteritis as a complication of Wiskott-Aldrich syndrome. J Pediatr. 1979;95:742-744[CrossRef][Medline] [Order article via Infotrieve].
87.
Zhu Q, Zhang M, Blaese RM, et al.
The Wiskott-Aldrich syndrome and X-linked congenital thrombocytopenia are caused by mutations of the same gene.
Blood.
1995;86:3797-3804 88. Villa A, Notarangelo L, Macchi P, et al. X-linked thrombocytopenia and Wiskott-Aldrich syndrome are allelic diseases with mutations in the WASP gene. Nat Genet. 1995;9:414-417[CrossRef][Medline] [Order article via Infotrieve].
89.
Litzman J, Jones A, Hann I, Chapel H, Strobel S, Morgan G.
Intravenous immunoglobulin, splenectomy, and antibiotic prophylaxis in Wiskott-Aldrich syndrome.
Arch Dis Child.
1996;75:436-439 90. Spickett GP, Farrant J, North ME, Zhang JG, Morgan L, Webster AD. Common variable immunodeficiency: how many diseases? Immunol Today. 1997;18:325-328[CrossRef][Medline] [Order article via Infotrieve]. 91. Cunningham-Ruddles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol. 1999;92:34-48[CrossRef][Medline] [Order article via Infotrieve]. 92. Uluhan A, Sager D, Jasin HE. Juvenile rheumatoid arthritis and common variable hypogammaglobulinemia. J Rheumatol. 1998;25:1205-1210[Medline] [Order article via Infotrieve]. 93. Washington K, Stenzel TT, Buckley RH, Gottfried MR. Gastrointestinal pathology in patients with common variable immunodeficiency and X-linked agammaglobulinemia. Am J Surg Pathol. 1996;20:1240-1252[CrossRef][Medline] [Order article via Infotrieve]. 94. Hammarstrom L, Vorechovsky I, Webster D. Selective IgA deficiency (SIgAD) and common variable immunodeficiency (CVID). Clin Exp Immunol. 2000;120:225-231[CrossRef][Medline] [Order article via Infotrieve]. 95. Kinlen LJ, Webster AD, Bird AG, et al. Prospective study of cancer in patients with hypogammaglobulinaemia. Lancet. 1985;2:263-266. 96. Ariatti C, Vivenza D, Capello D, et al. Common-variable immunodeficiency-related lymphoma associate with mutations and rearrangement of BCL-6: pathogenetic and histogenetic implications. Hum Pathol. 2000;31:871-873[CrossRef][Medline] [Order article via Infotrieve].
97.
Hermaszewski RA, Webster AD.
Primary hypogammaglobulinaemia: a survey of clinical manifestations and complications.
Q J Med.
1993;86:31-42
98.
Mullighan CG, Fanning GC, Chapel HM, Welsh KI.
TNF and lymphotoxin- 99. Fasano MB, Sullivan KE, Sarpong SB, et al. Sarcoidosis and common variable immunodeficiency. Report of 8 cases and review of the literature. Medicine (Baltimore). 1996;75:251-261[CrossRef][Medline] [Order article via Infotrieve]. 100. Sutor G, Fabel H. Sarcoidosis and common variable immunodeficiency. A case of a malignant course of sarcoidosis in conjunction with severe impairment of the cellular and humoral immune system. Respiration. 2000;67:204-208[CrossRef][Medline] [Order article via Infotrieve]. 101. Mechanic LJ, Dikman S, Cunningham-Rundles C. Granulomatous disease in common variable immunodeficiency. Ann Intern Med. 1997;127:613-617.
102.
Wright JJ, Wagner DK, Blaise RM, Hagengruber C, Waldmann TA, Fleisher TA.
Characterization of common variable immunodeficiency: identification of a subset of patients with distinctive immunophenotypic and clinical features.
Blood.
1990;76:2046-2051 103. Strober W, Sneller MC. IgA deficiency. Ann Allergy. 1991;66:363-375[Medline] [Order article via Infotrieve]. 104. Liblau RS, Bach JF. Selective IgA deficiency and autoimmunity. Int Arch Allergy Immunol. 1992;99:16-27[Medline] [Order article via Infotrieve].
105.
Cataldo F, Marino V, Ventura A, Bottaro G, Corazza GR.
Prevalence and clinical features of selective immunoglobulin A deficiency in coeliac disease: an Italian multicentre study. Italian Society of Paedatric Gastroenterology and Hepatology (SIGEP) and "Club del Tenue" Working Groups on Coeliac Disease.
Gut.
1998;42:362-365 106. Munks R, Booth JR, Sokol RJ. A comprehensive IgA service provided by a blood transfusion center. Immunohaematology. 1998;14:155-160. 107. Pineda AA, Taswell HF. Transfusion reactions associated with anti-IgA antibodies: report of four cases and review of the literature. Transfusion. 1975;15:10-15[Medline] [Order article via Infotrieve].
108.
Burks AW, Sampson HA, Buckley RH.
Anaphylactic reactions after
109.
Lilic D, Sewell WA.
IgA deficiency: what we should 110. Heikkila M, Koistinen J, Lohman M, Koskimies S. Increased frequencies of HLA-A1 and -B8 in association with total lack, but not with deficiency of serum IgA. Tissue Antigens. 1984;23:280-283[Medline] [Order article via Infotrieve]. 111. Levy A, Michel G, Lemerrer M, Philip N. Idiopathic thrombocytopenic purpura in two mothers of children with DiGeorge sequence: a new component manifestation of deletion 22q11. Am J Med Genet. 1997;69:356-359[CrossRef][Medline] [Order article via Infotrieve]. 112. DePiero AD, Lourie EM, Berman BW, Robin NH, Zinn AB, Hostoffer RW. Recurrent immune cytopenias in two patients with DiGeorge/velocardiofacial syndrome. J Pediatr. 1997;131:484-486[Medline] [Order article via Infotrieve]. 113. The International FMF Consortium. Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. Cell. 1997;90:797-807[CrossRef][Medline] [Order article via Infotrieve].
114.
Centola M, Wood G, Frucht DM, et al.
The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators.
Blood.
2000;95:3223-3231 115. Kastner DL. Familial Mediterranean fever: the genetics of inflammation. Hosp Pract (Off Ed). 1998;33:131-134[Medline] [Order article via Infotrieve]139-140, 143-146. 116. Ozen S. New interest in an old disease: familial Mediterranean fever. Clin Exp Rheumatol. 1999;17:745-749[Medline] [Order article via Infotrieve]. 117. Tekin M, Yalcinkaya F, Tumer N, Akar N, Misirhiogli M, Cakar N. Clinical, laboratory and molecular characteristics of children with familial Mediterranean fever-associated vasculitis. Acta Paediatr. 2000;89:177-182[CrossRef][Medline] [Order article via Infotrieve]. 118. Galon J, Aksentijevich I, McDermott MF, O'Shea JJ, Kastner DL. TNFRSF1A mutations and autoinflammatory syndromes. Curr Opin Immunol. 2000;12:479-486[CrossRef][Medline] [Order article via Infotrieve]. 119. McDermott MF, Aksentijevich I, Galon J, et al. Germline mutations in the extracellular domains of the 55kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes. Cell. 1999;97:133-144[CrossRef][Medline] [Order article via Infotrieve]. 120. Drenth JP, Cuisset L, Grateau G, et al. Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome. International Hyper IgD Study Group. Nat Genet. 1999;22:178-181[CrossRef][Medline] [Order article via Infotrieve]. 121. Kanegane H, Tsukada S, Iwata T, et al. Detection of Bruton's tyrosine kinase mutations in hypogammaglobulinaemic males registered as common variable immunodeficiency (CVID) in the Japanese Immunodeficiency Registry. Clin Exp Immunol. 2000;120:512-517[CrossRef][Medline] [Order article via Infotrieve]. 122. Plebani A, Ugazio AG, Meini A, et al. Extensive deletion of immunoglobulin heavy chain constant region genes in the absence of recurrent infections: when is IgG subclass deficiency clinically relevant? Clin Immunol Immunopathol. 1993;68:46-50[CrossRef][Medline] [Order article via Infotrieve].
123.
Farrington M, Grosmaire LS, Nonoyama S, et al.
CD40 ligand expression is defective in a subset of patients with common variable immunodeficiency.
Proc Natl Acad Sci U S A.
1994;91:1099-1103 124. Sawabe T, Horiuchi T, Nakamura M, et al. Defect of lck in a patient with common variable immunodeficiency. Int J Mol Med. 2001;7:609-614[Medline] [Order article via Infotrieve].
125.
Morra M, Silander O, Calpe S, et al.
Alterations of the X-linked lymphoproliferative disease gene SH2D1A gene in common variable immunodeficiency syndrome.
Blood.
2001;98:1321-1325 126. Sanal O, Ersoy F, Yel L, et al. Impaired IgG antibody production to pneumococcal polysaccharides in patients with ataxia-telangiectasia. J Clin Immunol. 1999;19:326-334[CrossRef][Medline] [Order article via Infotrieve]. 127. Shovlin CL, Simmonds HA, Fairbanks LD, et al. Adult onset immunodeficiency due to inherited adenosine deaminase deficiency. J Immunol. 1994;153:2331-2339[Abstract].
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  C. Samarghitean, C. Ortutay, and M. Vihinen Systematic Classification of Primary Immunodeficiencies Based on Clinical, Pathological, and Laboratory Parameters J. Immunol., December 1, 2009; 183(11): 7569 - 7575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bosticardo, F. Marangoni, A. Aiuti, A. Villa, and M. Grazia Roncarolo Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome Blood, June 18, 2009; 113(25): 6288 - 6295. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Vassallo, R. W. Newton, S. E. Chieng, M. R. Haeney, A. Shabani, and P. D. Arkwright Clinical variability and characteristic autoantibody profile in primary C1q complement deficiency Rheumatology, October 1, 2007; 46(10): 1612 - 1614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Aghamohammadi, N. Pouladi, N. Parvaneh, M. Yeganeh, M. Movahedi, M. Gharagolou, Z. Pourpak, N. Rezaei, A. Salavati, S. Abdollahzade, et al. Mortality and Morbidity in Common Variable Immunodeficiency J Trop Pediatr, February 1, 2007; 53(1): 32 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Vanasek, S. L. Nandiwada, M. K. Jenkins, and D. L. Mueller CD25+Foxp3+ Regulatory T Cells Facilitate CD4+ T Cell Clonal Anergy Induction during the Recovery from Lymphopenia J. Immunol., May 15, 2006; 176(10): 5880 - 5889. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D Shepshelovich and Y Shoenfeld Prediction and prevention of autoimmune diseases: additional aspects of the mosaic of autoimmunity Lupus, March 1, 2006; 15(3): 183 - 190. [Abstract] [PDF]
|
|
|
|
 |
|
 R Lakshman, S Bruce, D A Spencer, D Crawford, A Galloway, P N Cooper, D Barge, D Roos, T J Flood, and M Abinun Postmortem diagnosis of chronic granulomatous disease: how worthwhile is it? J. Clin. Pathol., December 1, 2005; 58(12): 1339 - 1341. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Knoechel, J. Lohr, E. Kahn, J. A. Bluestone, and A. K. Abbas Sequential development of interleukin 2-dependent effector and regulatory T cells in response to endogenous systemic antigen J. Exp. Med., November 21, 2005; 202(10): 1375 - 1386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Knoechel, J. Lohr, E. Kahn, and A. K. Abbas Cutting Edge: The Link between Lymphocyte Deficiency and Autoimmunity: Roles of Endogenous T and B Lymphocytes in Tolerance J. Immunol., July 1, 2005; 175(1): 21 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Schuster, F. Horn, and M. Borte Is hemophagocytic lymphohistiocytosis an autoimmune disease? Blood, September 18, 2002; 100(7): 2677 - 2677. [Full Text] [PDF]
|
|
|
|
|
|
R. Elhasid, R. Bergman, A. Etzioni, P. D. Arkwright, M. Abinun, and A. J. Cant Autoimmunity in severe combined immunodeficiency (SCID) Blood, September 18, 2002; 100(7): 2677 - 2678. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
), and there is an
increased risk of reactivating latent infection.